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Abstract
Background:  Vacuum-Assisted Breast Biopsy (VABB) is effective for the preoperative diagnosis of non-palpable
mammographic solid lesions. The main disadvantage is underestimation, which might render the management of atypical
ductal hyperplasia (ADH), and ductal carcinoma in situ (DCIS) difficult. This study aims to develop and assess a modified
way of performing VABB.
Patients and methods: A total of 107 women with non-palpable mammographic breast solid tumors BI-RADS 3 and
4 underwent VABB with 11G, on the stereotactic Fischer's table. 54 women were allocated to the recommended
protocol and 24 cores were obtained according to the consensus meeting in Nordesterdt (1 offset-main target in the
middle of the lesion and one offset inside). 53 women were randomly allocated to the extended protocol and 96 cores
were excised (one offset-main target in the middle of the lesion and 7 peripheral offsets). A preoperative diagnosis was
established. Women with a preoperative diagnosis of precursor/preinvasive/invasive lesion underwent open surgery. A
second pathologist, blind to the preoperative results and to the protocol made the postoperative diagnosis. The
percentage of the surface excised via VABB was retrospectively calculated on the mammogram. The discrepancy
between preoperative and postoperative diagnoses along with the protocol adopted and the volume removed were
evaluated by Fisher's exact test and Mann-Whitney-Wilcoxon test, respectively.
Results: Irrespectively of the protocol adopted, 82.2% of the lesions were benign. 14.0% of the lesions were malignancies
(5.1% of BI-RADS 3, 5.3% of BI-RADS 4A, 25% of BI-RADS 4B, and 83.3% of BI-RADS 4C lesions). 3.7% of the biopsies
were precursor lesions. There was no evidence of underestimation in either protocols. In the standard protocol, the
preoperative/postoperative diagnoses were identical. In the extended protocol, the postoperative diagnosis was less
severe than the preoperative in 55.5% of cases (55.5% vs. 0%, p = 0.029), and preoperative ADH was totally removed.
The phenomenon of discrepancy between diagnoses was associated with larger volume removed (8.20 ± 1.10 vs. 3.32 ±
3.50 cm3, p = 0.037) and higher removed percentage of the lesion (97.83 ± 4.86% vs. 74.34 ± 23.43%, p = 0.024)
Conclusion: The extended protocol seems to totally excise precursor lesions, with minimal underestimation. This
might possibly point to a modified management of ADH lesions.
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Background
The increased use of mammograms has led to the frequent
detection of breast lesions, which in turn require further
evaluation [1,2]. The most common mammographic
abnormalities found on screening examinations are
microcalcifications, solid lesions, and asymmetric densi-
ties [3,4]. About 90% of women with abnormal results do
not have breast cancer [5,6]. The Breast Imaging Reporting
and Data System (BI-RADS) was recommended by the
American College of Radiology in order to provide a com-
mon language to indisputably describe the degree of sus-
picion regarding a mammographic lesion [7-9]. BI-RADS
3 lesions are considered as probably benign with a risk for
malignancy less than 2% [7-9]. Suspicious lesions with a
substantial probability but without the classic appearance
of malignancy are classified as BI-RADS 4 [7,9,10]. Biopsy
should be considered in these lesions. BI-RADS 5 lesions
are highly suggestive of malignancy. It is recommended
that appropriate action should be taken [7-10].
To establish a preoperative diagnosis, excisional biopsies,
core needle biopsies [11-14] and vacuum-assisted breast
biopsies (VABB) have been used [15,16]. Vacuum-assisted
breast biopsy with stereotactic guidance has become an
important part of the work-up of patients with suspicious
breast lesions. The improved quality of vacuum-assisted
core biopsy specimens, superior calcification retrieval,
and accuracy, are well described in the literature [15-18].
Apart from the management of lesions with microcalcifi-
cations, VABB is an effective method for the evaluation of
non-palpable mammographic solid lesions without
microcalcifications [19].
Nonetheless, VABB has the disadvantage of histological
underestimation, which renders the management of atyp-
ical ductal hyperplasia (ADH), and ductal carcinoma in
situ (DCIS) somewhat difficult [20]. Up to 50% of the
lesions diagnosed as DCIS by VABB show foci of invasion
on pathological examination after surgical resection of
these lesions [21-23]. The underestimation of ADH ranges
in the literature from 0–35% [22].
This prompts an interesting question: does the removal of
larger volumes of breast tissue, obtained contiguously
from a single site in the breast at directional vacuum-
assisted 11-gauge needle biopsy, result in decreased
underestimation?
To answer this question, we have developed a modified
VABB procedure using a considerably greater number of
cores and offsets. The main objective of our study was:
(i) to compare the extended way of performing VABB and
the recommended way according to the consensus meet-
ing in Norderstedt.
(ii) to investigate the putative effects of greater volume
(cm3) excised on the management of non-palpable solid
lesions without microcalcifications.
Patients and methods
We present the Greek experience, since our Breast Unit is
the only center equipped with VABB and a Fischer's table.
The material of this study consisted of 107 procedures
performed from January 2004 to September 2006 in our
Unit on women with a median age of 53 (range 37–77)
years, (mean ± SD: 54.25 ± 9.58) for non-palpable solid
lesions of the breast without microcalcifications.
Within this period, 355 women with non-palpable mam-
mographic findings successfully underwent VABB; 107
biopsies were performed for mammographic solid tumor
without microcalcifications (239 biopsies for microcalci-
fications and 9 for asymmetric density).
Before VABB, all patients were evaluated by one of the two
radiologists of our Unit and a BI-RADS category was
assigned. For lesions categorized as BI-RADS 3, follow-up
was generally recommended. However, VABB was per-
formed in the cases where family history was strongly pos-
itive or when the patient and referring physician expressed
particular concern. In our unit, most of the BI-RADS cate-
gory 5 cases are directly submitted for surgical biopsy in
view of the great likelihood of cancer.
During this period of time, VABB was performed by 5 sur-
geons. In all instances, a radiologist was present to assist
in the targeting. All women were informed about the pro-
cedure by the surgeon performing the intervention. The
Mammotome biopsy was performed on a digital prone
table (Mammotest, Fischer Imaging, Denver, CO, USA),
using 11-gauge Mammotome vacuum probes, under local
anesthesia.
Women who underwent VABB were randomly allocated
to two standard protocols. The first category (recom-
mended protocol) included 54 women. We attempted to
obtain 24 cores from these women, according to the con-
sensus meeting in Nordesterdt. For this purpose, we used
1 offset-main target in the middle of the lesion and one
offset inside the solid lesion. 12 cores were excised from
each offset (12*2 = 24).
In the second category (extended protocol), which
included 53 women, we used one offset-main target in the
middle of the solid lesion and 7 peripheral offsets, each
one corresponding to a vertex of the hypothetically
inscribed canonical heptagon in the round lesion, i.e.
approximately 51 degrees away from each other. 12 cores
were excised from each offset [(7+1)*12 = 96] in each
patient of this group.World Journal of Surgical Oncology 2007, 5:53 http://www.wjso.com/content/5/1/53
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In both groups, a clip was placed in the biopsy site. After
VABB, a mammogram on the women confirmed the exci-
sion of the suspicious non-palpable solid tumor, showing
the cavitation in the suspicious area. The cores were exam-
ined by a pathologist and a preoperative diagnosis was
established.
Afterwards, all women (except for one woman in the
standard protocol group, to whom chemotherapy was
administered, because NHL was diagnosed) with a preop-
erative pathological diagnosis of ADH, DCIS, LN, or inva-
sive carcinoma, underwent open surgery under general
anesthesia using a hook-wire. A second pathologist, blind
to the preoperative results and to the protocol performed
on the patient, examined the tissue removed by the sur-
geon. Thus, a second, postoperative diagnosis was inde-
pendently and blindly made.
The percentage of the surface excised via VABB was retro-
spectively calculated on the mammogram, in the operated
women of both protocols. The remaining surface was
measured by calculating firstly the surface (cm2) of the
solid tumour. More precisely, we measured the two
dimensions of the solid tumour from the face mammo-
gram using a ruler. Using the same method, we estimated
the surface of the solid lesion that was left after VABB,
using the formula for the area of circle segments. The sub-
traction of the above surfaces yielded the surface of the
lesion excised. Also, the volume of specimens excised by
VABB was determined in these patients.
The association between pathological diagnosis and BI-
RADS classification, as well as the discrepancy between
preoperative and postoperative diagnoses along with the
protocol adopted were evaluated with the appropriate sta-
tistic, indicated in the results' section in parentheses. Sta-
tistical analysis was performed with STATA 8.0 statistical
software.
Permission has been obtained from the local institutional
review board for publication of the findings summarized
in this study.
Results
In 39 out of 107 women (36.4%) subjected to VABB, the
non-palpable solid tumor was characterized as BI-RADS 3
(probably benign). In 68 out of 107 procedures (63.6%)
the suspicious lesion was classified as BI-RADS 4. BI-
RADS 4A subclassification is presented in Table 1.
The specimens obtained by VABB revealed a benign lesion
in 88 out of 107 cases (82.2%), irrespective of their BI-
RADS classification. The predominant diagnoses were
fibrocystic changes, fibroadenoma, and adenosis/scleros-
ing adenosis; 32 out of 88 cases (36.4%) were fibrocystic
changes, 18 lesions out of 88 (20.5%) were fibroadeno-
mas, and 22 out of 88 lesions were adenoses/sclerosing
adenoses (25%). Epitheliosis with atypia (5.7%), papillo-
mas (4.5%) and haemangiomas (2.3%) were less com-
mon.
According to the pathological evaluation of the tissue
samples obtained by VABB, in 15 out of 107 cases (14%),
a malignancy was found, irrespective of the BI-RADS clas-
sification; 3.7% of the cases (4 out of 107) were precursor
lesions [two cases of ADH and two cases of lobular neo-
plasia (LN)] (Table 1). Ductal invasive carcinoma was the
predominant type (14 out of 15 malignant cases, 93.3%)
Irrespectively of the protocol adopted, there was a statisti-
cally significant increase in the probability of malignancy
along with the increasing severity of the BI-RADS classifi-
cation (p < 0.001, malignancy vs. all other diagnoses;
Fisher's exact test).
The random allocation of cases to the two protocols is
depicted in detail in Table 2. No statistically significant
differences were documented in the frequency of cancer
between the two protocols.
As described above, for each patient with a precursor or
malignant lesion [except for the patient with non-Hodg-
kin lymphoma (NHL), to whom chemotherapy was
administered], two pathological diagnosis existed, one
preoperative and one postoperative (Table 3). The patho-
logical diagnoses were identical in 50% of cases (Table 4).
Interestingly enough, there was no evidence of underesti-
mation of the lesion by VABB. On the contrary, in 5 cases
(all of them belonging to the extended protocol), the sur-
gical diagnosis on the remaining tissue was less severe
than that initially made by VABB. The above 5 cases com-
prised 4 cases of ductal invasive carcinoma and one case
of ADH.(Table 3, in bold).
The phenomenon of less severe postoperative diagnosis
was more frequent in the extended protocol (p = 0.029;
Fisher's exact test) (Table 4). As expected, less severe diag-
nosis based on the surgical specimen was associated with
larger volume removed by the VABB (p = 0.037; Mann-
Whitney-Wilcoxon test for independent samples) and the
higher removed percentage of the lesion (p = 0.024;
Mann-Whitney-Wilcoxon test for independent samples)
(Table 5).
Clinically significant haematoma developed in 5 out of
107 patients, 2 of them belonging to the standard proto-
col, and 3 to the extended protocol. None of them
required surgical intervention. The rate of clinically
important haematoma formation did not differ between
the two protocols. Similarly, there was no statistically sig-World Journal of Surgical Oncology 2007, 5:53 http://www.wjso.com/content/5/1/53
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nificant difference in the mean age of women between the
two protocols.
Finally, in 3 additional procedures (i.e. 3 out of 110),
VABB could not be performed, as the solid tumor was too
close to the examination plate; these 3 cases have not been
included the study.
Discussion
The use of VABB on the Fischer's table has been proven
effective for preoperative diagnosis of breast cancer [15],
with very satisfactory sensitivity, specificity, positive and
negative prognostic value [19]. Many studies have focused
on the role of VABB in the assessment of lesions with
microcalcifications [18,24]. Despite controversies, the
role of VABB in the management of lesions without
microcalcifications [21,25] has been documented.
The main disadvantage of VABB is underestimation [20-
22]. The underestimation rate ranges in ADH between 0–
35%, and in DCIS raises up to 50% [22,23]. It is not clear
in the international literature whether the underestima-
tion rate is higher in solid lesions or in microcalcifications
[20-22]. The suspicion for underestimation has prompted
to surgical intervention in the cases diagnosed as ADH, LN
by VABB [20,26]. Thus, the need for a procedure minimiz-
ing or even eliminating the underestimation problem
seems to be crucial in the clinical practice.
Interestingly, underestimation was not detected in either
protocol. In the standard protocol group, the relatively
small sample may account for this observation. However,
the excision of 96 cores implies a totally different context,
i.e. that of a quasi-total excision of the non-palpable solid
lesion. The quasi-total excision seems to encompass two
constituents: lack of underestimation and frequently no
residual precursor/preinvasive/invasive tissue being left
after VABB (as documented by the postoperative examina-
tion). No residual tissue after VABB has been occasionally
reported in the literature [27-29], but has not been exten-
sively studied.
With respect to the first constituent, total elimination of
underestimation might seem intriguing, for various rea-
sons. Results with larger (8G) needles have not led to the
diminishment of underestimation [30,31]. Indeed, the
needle size may be a crucial factor, but the setting of off-
sets and the number of cores excised may also be an
important factor determining underestimation. A hint to
this direction dates back to 2001, when Jackman et al.,
showed that obtaining of more than 10 specimens per
lesion leads to reduced underestimation of DCIS [32].
Table 1: Non-palpable mammographic solid lesions: BI-RADS classification and preoperative diagnosis by VABB
Preoperative diagnosis
Benign Precursor lesion Malignancy Total
BI-RADS 3 95% CI 37 (94.9%) 0 2 (5.1%) 0.6%–17.3% 39
BI-RADS 4A 95% CI 34 (89.4%) 2 (5.3%) 2 (5.3%) 0.6%–17.8% 38
BI-RADS 4B 95% CI 16 (66.7%) 2 (8.3%) 6 (25%) 9.8%–46.7% 24
BI-RADS 4C 95% CI 1 (16.7%) 0 5 (83.3%) 35.9%–99.6% 6
Total 88 4 15 107
Table 2: Allocation of cases to the two protocols.
Preoperative diagnosis
Benign Precursor lesions Malignant cases Total
Standard 
protocol
Extended 
protocol
Standard 
protocol
Extended 
protocol
Standard 
protocol
Extended 
protocol
BI-RADS 3 2 0 1 7 0020 3 9
BI-RADS 4A 1 6 1 8 1111 3 8
BI-RADS 4B 88113 a 32 4
BI-RADS 4C 0100236
Total 4 4 4 4 2287 1 0 7
a NHL was allocated to the standard protocol, but was not operatedWorld Journal of Surgical Oncology 2007, 5:53 http://www.wjso.com/content/5/1/53
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Although a contradictory study exists [33], the latter
adopted an upper limit of 20 specimens per case. As a
result, the context of 96 cores has remained unexplored,
to which the previous results cannot be projected with cer-
tainty.
Independently, it has been suggested that the radiological
disappearance of the lesion cannot enable the total elimi-
nation of underestimation, in the context of 18 cores
(range: 5–64 cores) [22]. However, it should be kept in
mind that radiological disappearance is not a synonym of
pathological disappearance. The context of 96 cores might
in fact go beyond the radiological disappearance, which
nevertheless is not totally reliable in lesions without
microcalcifications, as those examined in this study. At
any case, the sample size of our study is relatively small,
and more studies are undoubtedly needed to precise the
exact, putative percentage of underestimation which
might emerge in a large series, when 96 cores are excised.
With respect to the second constituent, i.e. the lack of
residual tissue, Liberman et al., (1998) have stated that the
complete removal of the mammographic lesion does not
ensure the complete excision of carcinomas [28]. Indeed,
the fact that free surgical borders cannot be achieved does
not permit any therapeutic implications with respect to
carcinomas. Of notice however, the whole cancerous
lesion was excised via VABB in 56% of the extended pro-
tocol cases, while there was sufficient invasive tissue for
the postoperative diagnosis of IDC in all cases assigned to
the standard protocol.
On the other hand, a quasi-total excision of ADH might
be a different case. When 96 cores were obtained, under-
estimation was not observed; this implies that a diagnosis
of ADH seems accurate, not harboring an underlying car-
cinoma. Indeed, the percentage of ADH in our series
(1.9%) was surprisingly low compared with the interna-
tional literature on non-palpable solid tumors [17-
Table 4: Summarized results in the two protocols
Offsets
2–3 offsets 8 offsets Total
Identical results from both procedures 94 1 3
Cases in which the blind pathological examination after surgery yielded a less severe diagnosis 05 5
Total 99 1 8
Table 3: Malignant and precursor lesions in the two protocols
Protocol BI-RADS Diagnosis by VABB Postoperative diagnosis
Standard 3 IDC IDC
Standard 3 IDC + LN IDC + LN
Standard 4A IDC + DCIS + LN IDC + DCIS + LN
Standard 4A ADH ADH
Standard 4B LN LN
Standard 4B IDC IDC + DCIS
Standard 4B IDC + DCIS IDC + DCIS
Standard 4C IDC IDC
Standard 4C IDC IDC
Extended 4A LN LN
Extended 4A IDC Papilloma
Extended 4B ADH Normal mammary tissue
Extended 4B IDC ADH
Extended 4B IDC + DCIS IDC + DCIS
Extended 4B IDC + DCIS IDC + DCIS
Extended 4C IDC ADH
Extended 4C IDC IDC
Extended 4C IDC Fibrocystic changes, apocrine metaplasia, epitheliosisWorld Journal of Surgical Oncology 2007, 5:53 http://www.wjso.com/content/5/1/53
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20,34,35]. That was probably due to the lack of underesti-
mation, i.e. no DCIS cases were mistakenly added to the
ADH group.
In parallel, given the total excision in the case of ADH,
interesting implications with respect to ADH manage-
ment arise. It would be tempting to recommend follow-
up for ADH cases after the performance of the extended
protocol, as accurate diagnosis plus total excision seem a
particularly attractive. At any case, more studies are
needed to ascertain whether the current management of
ADH might be modified. Liberman et al., (2002) have
shown that to 'excise' of to 'sample' a lesion does not exert
a significant effect on ADH underestimation; however, the
distinction between 'excision' and 'sampling' was made
within a range of less specimens, i.e. between 4 and 47
(median 15) specimens [36]. Nonetheless, and given that
recent studies on MRI-guided VABB with 9G needle did
not diminish underestimation of ADH [37], ADH still
remains an entity on which extended protocols should be
tested.
Commenting on the population on which this study was
based, most of the Mammotome biopsies were performed
on BI-RADS category 4 patients, the most common indi-
cator for the procedure [38,39]. The percentage of BI-
RADS 3 lesions was relatively high due to various reasons.
Firstly, because we are the only referral center in Greece to
which patients with a higher risk or positive family history
are sent from other Centers. Secondly, in many cases this
is due to the woman's persistence. The repeated examina-
tions at a 6-month interval and the re-evaluation of the
finding caused them such anxiety, depression, and
decrease in their quality of life, that they insisted on a
VABB.
In our sample, 86% of the women that underwent VABB
did not have breast cancer. All these women could have
potentially undergone unnecessary open surgery. The
malignancy rates were in accordance with the BI-RADS
classification, and exhibited a statistically significant
increasing trend along with the BI-RADS subgroups.
According to the literature, the frequency of cancer in BI-
RADS 3 lesions ranges from 0.5% to 2% [7,8]; in our sam-
ple, the observed frequency of malignancies was 5.1%.
Given the confidence intervals of the proportion (Table
1), this discrepancy is not statistically significant and
should be attributed to the relatively small size of the sam-
ple.
Finally, an important issue which should be addressed is
the complication rate. More cores obtained could be asso-
ciated with a higher degree of complications. However, in
this study, VABB was well tolerated by the patients, and
there was no significantly higher percentage of hae-
matoma in the extended protocol. Larger studies monitor-
ing the safety of the extended protocol seem though
indispensable.
Conclusion
This study presents and standardizes a new way of per-
forming VABB which seems capable of reducing underes-
timation. The use of one main and 7 peripheral offsets,
the excision of 96 cores, and the greatest excised volume
might also possibly point to a modified management of
women with ADH lesions. Further, comparative studies
on larger series are needed to evaluate and possibly estab-
lish the extended VABB protocol.
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